{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:53:33Z","timestamp":1777452813561,"version":"3.51.4"},"reference-count":54,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:p>Mixed cryoglobulinaemia vasculitis (CryoVas) is a small-vessel systemic vasculitis caused by deposition of mixed cryoglobulins and is characterized by a wide range of clinical symptoms. HCV is the primary cause of Cryo-Vas, which is associated with significant morbidity and mortality. The mortality rate among patients with HCV-associated CryoVas is 3x that of the general population, with a 63% 10-year survival rate. First-line treatment for CryoVas is anti-HCV therapy because viral clearance is associated with clinical improvement. The introduction of highly effective, interferon-free, direct-acting antiviral regimens provides additional treatment options for these patients. Here, we review recent studies investigating the effect of antiviral therapy on HCV-associated CryoVas and provide expert opinion for health-care professionals managing these patients.<\/jats:p>","DOI":"10.3851\/imp3246","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T06:16:55Z","timestamp":1542608215000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["Expert Opinion on Managing Chronic HCV in Patients with Mixed Cryoglobulinaemia Vasculitis"],"prefix":"10.1177","volume":"23","author":[{"given":"Anna Linda","family":"Zignego","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Interdepartmental Hepatology Center MASVE, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Michel","family":"Pawlotsky","sequence":"additional","affiliation":[{"name":"National Reference Center for Viral Hepatitis B, C and D, Department of Virology, H\u00f4pital Henri Mondor, Universit\u00e9 Paris-Est, Cr\u00e9teil, France"},{"name":"INSERM U955, Cr\u00e9teil, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bondin","sequence":"additional","affiliation":[{"name":"AbbVie, Inc., Chicago, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s, UPMC Univ Paris 06, UMR 7211, and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Paris, France"},{"name":"INSERM, UMR_S 959, F-75013, Paris, France"},{"name":"CNRS, FRE3632, F-75005, Paris, France"},{"name":"AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"key":"bibr1-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2015.02.017"},{"key":"bibr2-IMP3246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199211193272104"},{"key":"bibr3-IMP3246","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-117-7-573"},{"key":"bibr4-IMP3246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208642"},{"key":"bibr5-IMP3246","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13490"},{"key":"bibr6-IMP3246","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i3.327"},{"key":"bibr7-IMP3246","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32835b15f7"},{"key":"bibr8-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/art.30319"},{"key":"bibr9-IMP3246","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35620"},{"key":"bibr10-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.002"},{"key":"bibr11-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21190"},{"key":"bibr12-IMP3246","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31829d2abc"},{"key":"bibr13-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.10.001"},{"key":"bibr14-IMP3246","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.1.101"},{"key":"bibr15-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.006"},{"key":"bibr16-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(74)90852-3"},{"key":"bibr17-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.06.008"},{"key":"bibr18-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.02.010"},{"key":"bibr19-IMP3246","unstructured":"AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. (Updated 21 September 2017. Accessed 9 January 2018.) Available from http:\/\/www.hcvguidelines.org."},{"key":"bibr20-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"bibr21-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.004"},{"key":"bibr22-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21856"},{"key":"bibr23-IMP3246","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-313983"},{"key":"bibr24-IMP3246","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.6"},{"key":"bibr25-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27623"},{"key":"bibr26-IMP3246","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202770"},{"key":"bibr27-IMP3246","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-248518"},{"key":"bibr28-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.05.017"},{"key":"bibr29-IMP3246","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208339"},{"key":"bibr30-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28753"},{"key":"bibr31-IMP3246","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.03.006"},{"key":"bibr32-IMP3246","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.02.037"},{"key":"bibr33-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.09.158"},{"issue":"2","key":"bibr34-IMP3246","first-page":"613A","volume":"66","author":"Cristin D.","year":"2017","journal-title":"Hepatology"},{"key":"bibr35-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28297"},{"key":"bibr36-IMP3246","doi-asserted-by":"publisher","DOI":"10.2174\/1389450117666160208145432"},{"key":"bibr37-IMP3246","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.1636"},{"key":"bibr38-IMP3246","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312942"},{"key":"bibr39-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/art.34331"},{"key":"bibr40-IMP3246","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-10-245878"},{"key":"bibr41-IMP3246","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-253948"},{"key":"bibr42-IMP3246","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.06.011"},{"key":"bibr43-IMP3246","volume-title":"Package insert","author":"SOVALDI (sofosbuvir).","year":"2017"},{"key":"bibr44-IMP3246","volume-title":"Package insert","author":"HARVONI (ledipasvir and sofosbuvir).","year":"2017"},{"key":"bibr45-IMP3246","volume-title":"Package insert","author":"EPCLUSA (sofosbuvir and velpatasvir).","year":"2017"},{"key":"bibr46-IMP3246","volume-title":"Summary of Product Characteristics","author":"VOSEVI (sofosbuvir, velpatasvir and voxilaprevir).","year":"2017"},{"key":"bibr47-IMP3246","volume-title":"Package insert","author":"VOSEVI (sofosbuvir, velpatasvir and voxilaprevir).","year":"2017"},{"key":"bibr48-IMP3246","volume-title":"Summary of Product Characteristics","author":"MAVIRET (glecaprevir and pibrentasvir).","year":"2017"},{"key":"bibr49-IMP3246","volume-title":"Package insert","author":"MAVYRET (glecaprevir and pibrentasvir).","year":"2017"},{"key":"bibr50-IMP3246","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"bibr51-IMP3246","first-page":"1164","volume":"32","author":"Levine J.W.","year":"2005","journal-title":"J Rheumatol"},{"key":"bibr52-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/art.23305"},{"key":"bibr53-IMP3246","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28977"},{"key":"bibr54-IMP3246","doi-asserted-by":"publisher","DOI":"10.2147\/JIR.S114067"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:23Z","timestamp":1777380743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":54,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["10.3851\/IMP3246"],"URL":"https:\/\/doi.org\/10.3851\/imp3246","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}